You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. ViA-ML: A Machine Learning backed Visualization Assistant

    SBC: SCIENTIFIC SYSTEMS CO INC            Topic: OSD13LD1

    With the proliferation of cheap sensors, reduction in storage costs and the ubiquity of communication networks, Cyber-Physical Systems are collecting and storing data at an unprecedented rate. Analysis of such large databases is necessary to find relevant information and improve the efficiency of the Cyber Physical System. The goal of an analysis tool, simply put is to find the most interesting in ...

    SBIR Phase I 2014 Department of DefenseOffice of the Secretary of Defense
  2. Biometrics for Human-machine Team Feedback in Autonomous Systems

    SBC: TIAX LLC            Topic: OSD141AU1

    Use of Google Glass and add-ons to monitor warfighter state.

    SBIR Phase I 2014 Department of DefenseOffice of the Secretary of Defense
  3. Quality-Related eMeasures from EHR Data

    SBC: Commonwealth Informatics, Inc.            Topic: N/A

    To assess the readiness of EHR systems to support this new capability by constructing prototype eMeasure software, interfaced to at least one EHR system, that implements the chlamydia screening rate eMeasure based on HEDIS specifications for the numerator and denominator. Success in Plase I will support a Phase II activity to extend the prototype to additional EHR systems and additional existing a ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  4. Lab research for the development of human anti-diphtheria Mabs in CHO cells

    SBC: ANTAGEN BIOSCIENCES INC            Topic: N/A

    Monoclonal anitbodies (Mab) have been used successfully for treating human diseases. However, conventional Mabs are derived from mouse. Injection of murine Mabs into humans will cause adverse effects. The development of human Mabs against diphtheria could offer a commercially viable alternative to equine antitoxin for treating human diphtheria with a number of potential advantages including hig ...

    SBIR Phase I 2014 Department of Health and Human ServicesCenters for Disease Control and Prevention
  5. Development of Gap Junction Inhibition Therapy for Alcoholic Liver Disease

    SBC: HEPROTECH, INC.            Topic: NIAAA

    ? DESCRIPTION (provided by applicant): Alcoholic liver disease is a highly prevalent and costly condition affecting millions of people globally. Alcohol results in high morbidity and mortality an is responsible for nearly 4% of all deaths worldwide. Despite the tremendous societal and economic burden, there is no approved therapeutics for alcoholic liver disease. Instead, the standard of care ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Clinically suitable approach for gene-mediated therapy of cirrhosis.

    SBC: ADVANTAGENE, INC            Topic: NIAAA

    Abstract Persistent injury to the liver can cause chronic inflammation and dysregulated deposition of extracellular matrix (ECM), leading to accumulation of fibrotic scar tissue and eventually cirrhosis. While fibrosis is a normal wound healing response, in excess, it can further injure tissue and activate pro-fibrotic cells, resulting in a positive feedback loop. Scar tissue is not static, ECM re ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Novel Algorithm for Free Testosterone Determination

    SBC: FUNCTION PROMOTING THERAPIES LLC            Topic: NIA

    DESCRIPTION (provided by applicant): The measurement of testosterone levels is central to the diagnosis of androgen disorders in men and women. Circulating testosterone is bound largely to sex hormone binding globulin (SHBG) and albumin; only the unbound or free fraction is biologically active. Therefore, in conditions that affect SHBG concentrations, such as aging, obesity, and diabetes, the dete ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Compounds for Reducing Brain A-Beta Levels via Enhanced Systemic Clearance

    SBC: AKSTON BIOSCIENCES CORPORATION            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is characterized by progressively worsening dementia eventually leading to death. It affects over five million people in the United States and costs the healthcare system over 200 billion per year. Currently there is no available therapy for slowing, reversing or preventing the disease. There is strong evidence suggesting that AD ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Novel therapeutic for hematopoietic stem cell regeneration in bone marrow post my

    SBC: Minerva Biotechnologies Corporation            Topic: NIAID

    DESCRIPTION (provided by applicant): The purpose of this study is to establish in vivo proof of principle for a human therapeutic for hematopoietic stem cell regeneration in the bone marrow after myeloablation from radiation. Blood stem cells are the mostsusceptible to the effects of radiation and the most lethal. We have already demonstrated proof of principle for our therapeutic in vitro. If suc ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. A Novel Immunotolerizing Therapy for Autoimmune Vitiligo

    SBC: RADIKAL THERAPEUTICS, INC.            Topic: NIAMS

    DESCRIPTION (provided by applicant): Radikal Therapeutics (RTX) is pioneering a novel therapy to restore immune tolerance and arrest progressive depigmentation in vitiligo. At Loyola University (LUC), a variant to inducible Heat Shock Protein 70 was developed with remarkable potential for the prevention and treatment of autoimmune vitiligo. Carrying only a single amino acid modification to the pro ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government